16 45 16 14 1

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to the Box DD, Commissioner for Patents, Washington, D.C. 20231, on the date shown below

date shown below.				
Date P sanuary 25, 2002	By:	Kay L. Gaviglio	- lange	C. 4
FEB 1 1 2002		V	Docket N	PATENT No. GC527C3
~ <u>\$</u>	STATES PAT	ENT AND TRADEMA	ARK OFFICE	_
A TRADEUS	,			TECH
In re Application of)			当
David Estell & Fiona Harding	ý	Group Art Unit:	1645	CENT CENT
Serial No.: 09/768,080	8,080) Examiner: Unassigned)		FEB 1 5 2002 CENTER 1600/2900	
Filed: January 23, 2001	ý			2002 1600/2
For: PROTEINS PRODUCING ALTERED IMMUNOGENIO RESPONSE AND METHO MAKING AND USING THE	C) DDS OF)			306
In	formation Disc	closure Statement		
Box DD Commissioner for Patents Washington, DC 20231				
Sir:				
Applicants submit herewith pate Form PTO-1449 and attached the material to the examination of the disclose in accordance with 37 (nereto) of which	n they are aware, tha	t they believe m	nay be
This Information Disclosure Stat	tement:			
(a)☐ accompar §1.97(a).	nies the new pa	itent application subr	nitted herewith.	37 CFR
	er the date of er	ns after the filing date ntry into the national		
(c)⊠ as far as i first Office Action		undersigned, is filed	before the mail	ing date of a
(d) is filed aft	er the first Offic	ce Action and more th	nan three month	ns after the

	application filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and is accompanied by either the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Authorization to charge Deposit Account No. 07-1048 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement is provided in the Transmittal Letter submitted herewith in duplicate.
(e)	is filed after the mailing date of either a final rejection or a notice of allowance, whichever occurred first, and is accompanied by authorization (in the Transmittal Letter submitted herewith in duplicate) to charge Deposit Account No. 07-1048 the fee (\$180.00) set forth in 37 CFR §1.17(I)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Supplemental Information Disclosure Statement.
[If either of be	oxes (d) or (e) is checked above, the following "certification" under 37 CFR
§1.97(e) may	need to be completed.] The undersigned certifies that:
	Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
	No item of information contained in this Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
A copy of som	e of the items on Form PTO-1449 is supplied (See paragraph below): PCT
	search Report for PCT/ US 01/02204, filed January 22, 2001 with attached
patents and pu	
Those patent(s) or publication(s) which are marked with an asterisk (*) on the attached Form
PTO-1449 are	not supplied because they were previously cited by or submitted to the Office in
a prior applica	tion, Serial No. 09/060,872 filed April 15, 1998, and relied upon in this application
for an earlier f	ling date under 35 USC 120.
[×] eac	h

Serial No. 09/768,080 Page 3

A concise explanation of relevance of the items listed on PTO-1449 is:

□ given for each listed item
 □ given for only non-English language listed item(s)

in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: January 25, 2002

Christopher L. Stone Registration No. 35,696

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304-1013

Tel: 650 846-7555 Fax: 650 845-6504